CA2500531A1 - Method for treating or preventing metastasis of colorectal cancers - Google Patents

Method for treating or preventing metastasis of colorectal cancers Download PDF

Info

Publication number
CA2500531A1
CA2500531A1 CA002500531A CA2500531A CA2500531A1 CA 2500531 A1 CA2500531 A1 CA 2500531A1 CA 002500531 A CA002500531 A CA 002500531A CA 2500531 A CA2500531 A CA 2500531A CA 2500531 A1 CA2500531 A1 CA 2500531A1
Authority
CA
Canada
Prior art keywords
polypeptide
colorectal cancer
group
mlxs
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002500531A
Other languages
English (en)
French (fr)
Inventor
Yusuke Nakamura
Yoichi Furukawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
The University of Tokyo
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2500531A1 publication Critical patent/CA2500531A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
CA002500531A 2002-09-30 2003-08-14 Method for treating or preventing metastasis of colorectal cancers Abandoned CA2500531A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41470902P 2002-09-30 2002-09-30
US60/414,709 2002-09-30
PCT/JP2003/010338 WO2004031774A2 (en) 2002-09-30 2003-08-14 Method for treating or preventing metastasis of colorectal cancers

Publications (1)

Publication Number Publication Date
CA2500531A1 true CA2500531A1 (en) 2004-04-15

Family

ID=32069759

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002500531A Abandoned CA2500531A1 (en) 2002-09-30 2003-08-14 Method for treating or preventing metastasis of colorectal cancers
CA002500538A Abandoned CA2500538A1 (en) 2002-09-30 2003-08-14 Method for treating or preventing metastasis of colorectal cancers

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002500538A Abandoned CA2500538A1 (en) 2002-09-30 2003-08-14 Method for treating or preventing metastasis of colorectal cancers

Country Status (6)

Country Link
US (1) US20060210576A1 (enExample)
EP (2) EP1546730A2 (enExample)
JP (2) JP2006500945A (enExample)
AU (2) AU2003256075A1 (enExample)
CA (2) CA2500531A1 (enExample)
WO (2) WO2004031775A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240425A1 (en) * 2002-09-30 2006-10-26 Oncotherapy Science, Inc Genes and polypeptides relating to myeloid leukemia
WO2007026355A2 (en) * 2005-08-29 2007-03-08 Yeda Research And Development Co. Ltd. Modulators of cell migration and methods of identifying same
EP2180320A1 (en) * 2006-06-05 2010-04-28 Shimadzu Corporation Tumor marker and method for determination of the occurence of cancerous disease
DE102006035393A1 (de) * 2006-11-02 2008-05-15 Signature Diagnostics Ag Prognostische Marker für die Klassifizierung des dreijährigen progessionsfreien Überlebens von Patienten mit Kolonkarzinomen basierend auf Expressionsprofilen von biologischen Proben
WO2008089035A1 (en) * 2007-01-11 2008-07-24 Genentech, Inc. Genetic variations associated with tumors
JP5548872B2 (ja) * 2010-08-26 2014-07-16 株式会社島津製作所 大腸がん肝転移マーカー、及び試料中の大腸がん肝転移マーカーの分析方法
US20200391053A1 (en) * 2019-06-13 2020-12-17 Canon Medical Systems Corporation Radiotherapy system, therapy planning support method, and therapy planning method
CN115490758A (zh) * 2021-06-17 2022-12-20 温州医科大学 一种用于治疗或辅助治疗结直肠癌的抗肿瘤多肽ccr313及其应用
CN117801060A (zh) * 2022-09-26 2024-04-02 深圳碳云智肽药物科技有限公司 一种抗肿瘤多肽及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077568A1 (en) * 2000-09-15 2003-04-24 Gish Kurt C. Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
AU2002343443A1 (en) * 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis

Also Published As

Publication number Publication date
WO2004031774A3 (en) 2004-10-14
AU2003257849A8 (en) 2004-04-23
EP1546731A2 (en) 2005-06-29
AU2003257849A1 (en) 2004-04-23
US20060210576A1 (en) 2006-09-21
CA2500538A1 (en) 2004-04-15
WO2004031775A3 (en) 2004-10-14
JP2006501465A (ja) 2006-01-12
JP2006500945A (ja) 2006-01-12
WO2004031775A2 (en) 2004-04-15
AU2003256075A1 (en) 2004-04-23
EP1546730A2 (en) 2005-06-29
AU2003256075A8 (en) 2004-04-23
WO2004031774A2 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
EP1556518B1 (en) Genes and polypeptides relating to human pancreatic cancers
US20050259483A1 (en) Genes and polypeptides relating to prostate cancers
US7521205B2 (en) Genes and polypeptides relating to prostate cancers
WO2006085684A9 (en) Method of diagnosing bladder cancer
EP1668354A2 (en) Method of diagnosing breast cancer
CA2500405A1 (en) Genes and polypeptides relating to human myeloid leukemia
EP1551998A2 (en) Method for diagnosing non-small cell lung cancers
US20070054849A1 (en) Method for diagnosing hepatocellular carcinomas
US20060281081A1 (en) Method of diagnosing colon and gastric cancers
US20060210576A1 (en) Method for treating or preventing metastasis of colorectal cancers
US20070202109A1 (en) Method Of Diagnosing Breast Cancer
US20060111314A1 (en) Method for treating or preventing metastasis of colorectal cancers
US8067153B2 (en) Genes and polypeptides relating to prostate cancers
US20060240425A1 (en) Genes and polypeptides relating to myeloid leukemia
EP1727831A1 (en) Genes and polypeptides relating to prostate cancers

Legal Events

Date Code Title Description
FZDE Discontinued